Oral Shigellosis Vaccine
This application claims a Salmonella typhi Ty21a construct comprising a Shigella sonnei O-antigen biosynthetic gene region inserted into the Salmonella typhi Ty21a chromosome, where heterologous Shigella sonnei form 1 O-antigen is stably expressed together with homologous Salmonella typhi O-antigen. The constructs of this invention elicit immune protection against virulent Shigella sonnei challenge, as well as Salmonella Typhi challenge. Also claimed in this application are methods of recombineering a large antigenic gene region into a bacterial chromosome.
Bacillary dysentery and enteric fevers continue to be important causes of morbidity in both developed and developing nations. Shigella cause greater than one hundred and fifty million cases of dysentery and enteric fever occurs in greater than twenty-seven million people annually. Currently, there is no licensed vaccine to prevent the occurrence of shigellosis. Increasing multiple resistance in Shigella commonly thwarts local therapies.
IC:
FDA
NIH Ref. No.:
E-168-2012/0
TAB No:
TAB-2528
Advantages: Low cost production
Lower cost vaccine
Oral vaccine – no needles required
Temperature-stable manufacturing process - avoids need for refrigeration during vaccine distribution
Applications: One component of a multivalent Shigellosis vaccine under development
Research tool
Deve...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: admin Source Type: research
More News: Dysentery | Gastroenteritis | Genetics | Infectious Diseases | Research | Salmonella | Typhoid | Typhoid Vaccine | Vaccines | Veterinary Vaccinations